BOSTON — Odyssey Therapeutics Inc. said Tuesday that it has appointed Jolie M. Siegel as Executive Vice President and General Counsel as the clinical-stage biopharmaceutical company advances its pipeline of therapies for autoimmune and inflammatory diseases.
In her new role, Siegel will lead Odyssey’s legal, compliance, governance, and risk management functions, and will serve as a strategic partner to the company’s executive team and Board of Directors. Her responsibilities will include oversight of corporate governance and compliance, securities matters, intellectual property, and contractual and transactional activities as Odyssey continues to expand its immunology portfolio.
“Jolie’s appointment comes at an important stage in Odyssey’s development,” said Gary D. Glick, Ph.D., Founder and Chief Executive Officer of Odyssey Therapeutics. “As our portfolio advances and the company evaluates strategic opportunities, her experience advising biotechnology companies through growth and transactions will be a significant asset. Jolie’s leadership will help ensure we continue to build the right legal and governance foundation for the long term.”
Siegel brings more than 20 years of legal and business experience across biotechnology, life sciences, and technology companies. Most recently, she served as Chief Legal Officer and Corporate Secretary at C4 Therapeutics, where she oversaw legal, intellectual property, and corporate compliance matters during a period of significant company growth. Prior to that, she was Vice President, General Counsel and Corporate Secretary at Neon Therapeutics, supporting the company through its acquisition by BioNTech SE.
Earlier in her career, Siegel served as Senior Vice President and Deputy General Counsel at Intralinks Holdings, including during the company’s sale, and was a partner at Choate, Hall & Stewart LLP. In private practice, she advised venture-backed, private equity-backed, and high-growth companies on corporate governance, securities, and strategic transactions.
“I am excited to join Odyssey because of its mission to advance therapies for patients with autoimmune and inflammatory diseases—conditions that can be profoundly disruptive to patients and families,” Siegel said. “That mission is deeply personal to me, having seen the impact of diseases like Crohn’s and ulcerative colitis on close friends and their families. I’m excited to work with the Odyssey team and Board of Directors to help build a sustainable company capable of delivering long-term impact for patients.”
Siegel holds a Juris Doctor degree from the University of Pennsylvania Law School and a Bachelor of Arts, cum laude, in political science from the University of Pennsylvania.
